600062 Stock Overview
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
China Resources Double-Crane Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.56 |
| 52 Week High | CN¥22.22 |
| 52 Week Low | CN¥14.80 |
| Beta | 0.12 |
| 1 Month Change | -2.05% |
| 3 Month Change | 18.78% |
| 1 Year Change | 12.97% |
| 3 Year Change | 73.50% |
| 5 Year Change | 51.29% |
| Change since IPO | 622.24% |
Recent News & Updates
China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 24
Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel
Mar 02Shareholder Returns
| 600062 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.6% | -1.5% | -0.4% |
| 1Y | 13.0% | -16.0% | -17.6% |
Return vs Industry: 600062 exceeded the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 600062 exceeded the CN Market which returned -17.8% over the past year.
Price Volatility
| 600062 volatility | |
|---|---|
| 600062 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 600062 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600062's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 12,269 | Wenchao Lu | www.dcpc.com |
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for hypertension, diabetes, hypercholesterolemia, gastrointestinal care, and pediatric care, as well as peritoneal dialysis solution. It also provides injections for acute craniocerebral trauma, viral pneumonia and bronchitis, infectious diseases, calcium deficiency, metabolic acidosis, vitamin B and C deficiency, chronic severe pain, drug-resistant bacteria, and hypovolemia.
China Resources Double-Crane Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600062 fundamental statistics | |
|---|---|
| Market cap | CN¥20.99b |
| Earnings (TTM) | CN¥1.33b |
| Revenue (TTM) | CN¥10.22b |
15.7x
P/E Ratio2.1x
P/S RatioIs 600062 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600062 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.22b |
| Cost of Revenue | CN¥4.61b |
| Gross Profit | CN¥5.62b |
| Other Expenses | CN¥4.28b |
| Earnings | CN¥1.33b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 1.31 |
| Gross Margin | 54.93% |
| Net Profit Margin | 13.04% |
| Debt/Equity Ratio | 2.2% |
How did 600062 perform over the long term?
See historical performance and comparison